Influenza-B Victoria

Influenza-B Virus Victoria/504/00
Cat. No.
BT27920
Source
Synonyms
Appearance
Sterile Filtered colorless solution.
Purity
Greater than 90.0% as determined by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock
Quick Inquiry

Description

Allantoic fluid of 10 days old embryonated eggs, inoculated with influenza B virus, strain B/Victoria/504/00. The Influenza B Virus was purified by Ultracentrifugation with 10-40 % sucrose gradient.

Product Specs

Introduction
Influenza B virus, a member of the Orthomyxoviridae family, exclusively infects humans and seals. Unlike Influenza A virus, its mutation is limited to genetic drift and reassortment. Its evolutionary rate falls between Influenza A and C viruses, mutating 2-3 times slower than type A. This mutation rate, however, prevents lasting immunity. The virus structure includes an envelope, a capsid comprising a matrix protein, envelope, nucleoprotein complex, nucleocapsid, and a polymerase complex. Morphologically, it varies between spherical and filamentous forms. The surface displays approximately 500 projections of hemagglutinin and neuraminidase. The genome comprises eight linear negative-sense, single-stranded RNA segments, totaling 14648 nucleotides. Each segment is individually encapsidated within a nucleocapsid, all of which are enveloped.
Description
This product consists of allantoic fluid harvested from 10-day-old embryonated eggs inoculated with the B/Victoria/504/00 strain of influenza B virus. The virus underwent purification via ultracentrifugation using a 10-40% sucrose gradient.
Inactivation
The product has been treated with thimerosal and beta-propiolactone for inactivation, adhering to established inactivation protocols. Handling should be conducted in accordance with good laboratory practices for safe microbiological and viral handling.
Physical Appearance
The product is a sterile-filtered, colorless solution.
Formulation
The B/Victoria/53/99 solution is formulated with STE, 0.1% sodium azide (NaN3), and 0.005% thimerosal.
Stability
While the B/Victoria/504/00 strain remains stable at 4°C for up to 4 weeks, storage below -18°C is recommended. Repeated freezing and thawing should be avoided.
Applications
This product is suitable for serological investigations of influenza B virus and as an immunogen for antibody production.
Purity
The product exhibits a purity greater than 90% as determined by SDS-PAGE analysis.
Note
This product contains thimerosal (0.005%) and sodium azide (0.1%) as preservatives. Exercise caution during handling despite the low concentrations.
Immunological Activity
Tested with anti-influenza B monoclonal antibodies in ELISA.

Product Science Overview

Introduction

Influenza B virus is one of the three types of influenza viruses that cause seasonal flu epidemics in humans. Unlike Influenza A, which is known for causing pandemics, Influenza B is typically associated with less severe outbreaks. However, it still poses a significant public health concern. Among the various strains of Influenza B, the Victoria lineage, particularly the B/Victoria/504/00 strain, has been extensively studied for its unique characteristics and impact on human health.

Discovery and Classification

The B/Victoria/504/00 strain was first isolated in the year 2000. It belongs to the Victoria lineage of Influenza B viruses, which is one of the two main lineages, the other being the Yamagata lineage . These lineages are antigenically distinct, meaning they have different surface proteins that trigger immune responses in humans .

Genetic and Antigenic Properties

The B/Victoria/504/00 strain, like other Influenza B viruses, has a segmented RNA genome. This allows for genetic reassortment, which can lead to the emergence of new strains. The surface proteins hemagglutinin (HA) and neuraminidase (NA) are crucial for the virus’s ability to infect host cells and spread . The HA protein of B/Victoria/504/00 has been a focal point of research due to its role in binding to host cell receptors and initiating infection .

Epidemiology

Since its discovery, the B/Victoria/504/00 strain has been a part of seasonal influenza outbreaks worldwide. It has been included in the formulation of seasonal flu vaccines to provide immunity against this specific strain . The strain has shown a preference for infecting certain cell types in the human respiratory tract, which has implications for its transmission and pathogenicity .

Immune Response and Vaccine Development

Research has shown that the B/Victoria/504/00 strain induces a strong immune response in humans. This includes the production of antibodies that target the HA and NA proteins . However, the effectiveness of these antibodies can vary depending on the genetic makeup of the circulating strains. This has led to ongoing efforts to improve the match between vaccine strains and circulating viruses .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Category

Service

Related Products

Influenza B Antibody
Influenza-B Jiangsu/10/2003 Hemagglutinin, Rabbit Antibody
Cat. No.
BT4648
Source
Influenza-B Florida
Influenza-B Virus Florida 07/04
Cat. No.
BT27500
Source
Influenza-B Jilin
Influenza-B Virus Jilin 20/2003 Recombinant
Cat. No.
BT27596
Source
Baculovirus Insect Cells.
Influenza-B Qingdao
Influenza-B Virus Qingdao/102/91
Cat. No.
BT27773
Source
THE BIOTEK
THE BioTek is a global biotech company offering highly purified proteins for research in cancer, apoptosis, development, endocrinology, immunology, neuroscience, proteases, and stem cells.
  • Contact
  • Address: 1925 E Maple Ave, El Segundo, CA 90245 United States
  • Phone : +1 201-285-7826
  • Email : info@thebiotek.com
  • Hours : Mon.-Fri. 9:00 AM - 5:00 PM
© Copyright 2024 Thebiotek. All Rights Reserved.